US5234906A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hyperglycemic compositions
Assignee: Amylin Pharmaceuticals LLC
•
Filing: 1991-01-10
•
Granted: 1993-08-10
•
Expires: 2011-01-10
Abstract
Abstract Compositions having amylin or an amylin agonist and a glucagon compound, particularly peptide compounds, for the control of glucose production in mammals are provided. The compositions are useful in the treatment of hypoglycemia, including acute hypoglycemic conditions such as those brought on by insulin overdose and the overuse of oral hypoglycemic agents.
Inventors
- 👤 Andrew Young
- 👤 Garth J. S. Cooper
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 10:14
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/0004; A61K49/0008; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/225; A61K38/26; A61P; A61P3/00; A61P3/08
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
15 words
A composition comprising glucagon and an amylin admixed in a form suitable for therapeutic administration.
Claim 2
Dependent Claim
15 words
A composition comprising glucagon and an amylin admixed in a form suitable for therapeutic administration.
Claim 3
Dependent Claim
18 words
A composition comprising a glucagon compound and an amylin agonist admixed in a form suitable for therapeutic administration.
Claim 4
Dependent Claim
18 words
A composition comprising a glucagon compound and an amylin agonist admixed in a form suitable for therapeutic administration.
Claim 5
Dependent Claim
11 words
The composition of claim 1 wherein said amylin is rat amylin.
Claim 6
Dependent Claim
14 words
The composition of claim 2 wherein said amylin agonist is a calcitonin gene-related peptide.
Claim 7
Dependent Claim
17 words
The composition of any of claims 1, 2 or 3 which is in lyophilized dosage unit form.
Claim 8
Independent Claim
30 words
A method for enhancing glucose levels in a mammal, which comprises the administration of a therapeutically effective amount of the composition of any of claims 1, 2, 3 or 4.
Claim 9
Independent Claim
31 words
A method for the treatment of acute hypoglycemia in mammals, which comprises the administration of a therapeutically effective amount of the composition of any of claims 1, 2, 3 or 4.
Claim 10
Dependent Claim
12 words
The method of claim 6 wherein said administration is by parenteral injection.
Claim 11
Dependent Claim
12 words
The method of claim 7 wherein said administration is by parenteral injection.
Claim 12
Dependent Claim
12 words
The method of claim 6 wherein said administration is by intravenous infusion.
Claim 13
Dependent Claim
12 words
The method of claim 7 wherein said administration is by intravenous infusion.
Claim 14
Independent Claim
26 words
A method for the control of hypoglycemic conditions in mammals, which comprises the co-administration of therapeutically effective amounts of a glucagon compound and an amylin agonist.
Claim 15
Independent Claim
26 words
A method for the control of hypoglycemic conditions in mammals, which comprises the co-administration of therapeutically effective amounts of a glucagon compound and an amylin agonist.
Claim 16
Dependent Claim
11 words
The method of claim 12 wherein said amylin agonist is amylin.
Claim 17
Dependent Claim
14 words
The method of claim 12 wherein said amylin agonist is a calcitonin gene-related peptide.
Claim 18
Independent Claim
26 words
A method for the treatment of acute hypoglycemia in mammals, which comprises the co-administration of therapeutically effective amounts of a glucagon compound and an amylin agonist.
Claim 19
Independent Claim
26 words
A method for the treatment of acute hypoglycemia in mammals, which comprises the co-administration of therapeutically effective amounts of a glucagon compound and an amylin agonist.
Claim 20
Dependent Claim
11 words
The method of claim 15 wherein said amylin agonist is amylin.
Claim 21
Dependent Claim
14 words
The method of claim 15 wherein said amylin agonist is a calcitonin gene-related peptide.
Claim 22
Dependent Claim
11 words
The composition of claim 1 wherein said amylin is human amylin.
Claim 23
Dependent Claim
21 words
The composition of claim 2 wherein said amylin agonist comprises an amylin having a proline residue at amino acid position 29.
Claim 24
Dependent Claim
21 words
The composition of claim 2 wherein said amylin agonist comprises an amylin having a leucine residue at amino acid position 23.
Claim 25
Dependent Claim
21 words
The method of claim 12 wherein said amylin agonist comprises an amylin having a proline residue at amino acid position 29.
Claim 26
Dependent Claim
21 words
The method of claim 15 wherein said amylin agonist comprises an amylin having a proline residue at amino acid position 29.
Claim 27
Dependent Claim
21 words
The method of claim 12 wherein said amylin agonist comprises an amylin having a leucine residue at amino acid position 23.
Claim 28
Dependent Claim
21 words
The method of claim 15 wherein said amylin agonist comprises an amylin having a leucine residue at amino acid position 23.
References Cited (Backward Citations)
US4826763A
Cited
EP0309100A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-08-09 | 1997-02-08 | 1997-08-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-08-09 | 2001-02-08 | 2001-08-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-08-09 | 2005-02-08 | 2005-08-10 | $7700.00 | Window Closed / Lapsed |